Display options
Cite
Perri-Plandé J, Miremont-Salamé G, Micallef J, et al. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021;45(1):37-44doi: 10.1007/s40264-021-01124-5.
Perri-Plandé, J., Miremont-Salamé, G., Micallef, J., Herman, C., Baumevieille, M., Abriat, F., Lapeyre-Mestre, M., Haramburu, F., Daveluy, A. (2022). A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug safety, 45(1), 37-44. https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé, Joelle, et al. "A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019)." Drug safety vol. 45,1 (2022): 37-44. doi: https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29. PMID: 34714529.
Copy Download .nbib Format: NLM
Share it on

Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29.

A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Drug safety

Joelle Perri-Plandé, Ghada Miremont-Salamé, Joëlle Micallef, Cameron Herman, Marie Baumevieille, Frédéric Abriat, Maryse Lapeyre-Mestre, Françoise Haramburu, Amélie Daveluy,

Affiliations

  1. Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, Hôpital Pellegrin, CHU, 33076, Bordeaux Cedex, France.
  2. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team, Pharmacoepidemiology, UMR 1219, Bordeaux, France.
  3. Aix Marseille Univ, AP-HM, INSERM, Inst Neurosci Syst, Service de Pharmacologie Clinique et Pharmacovigilance, Marseille, France.
  4. Centre d'Addictovigilance, CHU, UMR-INSERM 1027, Toulouse, France.
  5. Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, Hôpital Pellegrin, CHU, 33076, Bordeaux Cedex, France. [email protected].
  6. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team, Pharmacoepidemiology, UMR 1219, Bordeaux, France. [email protected].

PMID: 34714529 DOI: 10.1007/s40264-021-01124-5

Abstract

INTRODUCTION: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade.

METHODS: A cross-sectional, national, multicentre survey study was conducted that included surveys taken every year from 2007 to 2019 in a national sample of 1500 randomly selected dispensing pharmacies.

RESULTS: The mean age of patients, mostly women (around 60%), remained stable over the study period (63.2 ± 17.1 years in 2007, 68.2 ± 17.2 years in 2019). The proportion of patients treated for more than 3 months increased from 2007 to 2019. Most prescriptions involved morphine, oxycodone and fentanyl (98.5% of all prescriptions in 2019). Morphine prescriptions dropped dramatically from 49.6% (2007) to 32.3% (2019) of the total narcotic analgesics. Fentanyl prescriptions varied from 40.1% in 2007 to 32.2% in 2019. Prescriptions of oxycodone, regardless of the indication, increased steadily from 2007, from 8.3 to 34% in 2019, becoming the most prescribed narcotic analgesic for the first time since the beginning of the survey.

CONCLUSIONS: This study demonstrates how narcotic opioids are prescribed, thanks to the active participation of health professionals, and confirms the striking increase in the prescription of oxycodone.

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

References

  1. Chang HY, Daubresse M, Kruszewski SP, Alexander GC. Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. Am J Emerg Med. 2014;32:421–31. https://doi.org/10.1016/j.ajem.2014.01.015 . - PubMed
  2. Christie D. “The analgesic abuse syndrome”: an epidemiological perspective. Int J Epidemiol. 1978;7:139–43. https://doi.org/10.1093/ije/7.2.139 . - PubMed
  3. Lalic S, Ilomaki J, Bell JS, Korhonen MJ, Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol. 2019;85:202–15. https://doi.org/10.1111/bcp.13792 . - PubMed
  4. Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, et al. Ten-year trend of opioid and non-opioid analgesic use in the French adult population. Br J Clin Pharmacol. 2021;87:555–64. https://doi.org/10.1111/bcp.14415 . - PubMed
  5. Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84:1324–34. https://doi.org/10.1111/bcp.13564 . - PubMed
  6. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181:891–6. https://doi.org/10.1503/cmaj.090784 . - PubMed
  7. Hauser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2: e599. https://doi.org/10.1097/pr9.0000000000000599 . - PubMed
  8. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther. 2010;88:307–17. https://doi.org/10.1038/clpt.2010.154 . - PubMed
  9. Morley KI, Ferris JA, Winstock AR, Lynskey MT. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain. 2017;158:1138–44. https://doi.org/10.1097/j.pain.0000000000000892 . - PubMed
  10. Wegrzyn EL, Chaghtai AM, Argoff CE, Fudin J. The CDC opioid guideline: proponent interpretation has led to misinformation. Clin Pharmacol Ther. 2018;103:950–3. https://doi.org/10.1002/cpt.1062 . - PubMed
  11. Soeiro T, Pradel V, Lapeyre Mestre M, Micallef J. Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Pain. 2021;162:770–7. https://doi.org/10.1097/j.pain.0000000000002093 . - PubMed
  12. van Amsterdam J, Pierce M, van den Brink W. Is Europe facing an emerging opioid crisis comparable to the U.S.? Ther Drug Monit. 2021;43:42–51. https://doi.org/10.1097/ftd.0000000000000789 . - PubMed
  13. Baumevieille M, Daveluy A, Maurain C, Bégaud B, Haramburu F. Medicines submitted to narcotics regulations in France, 1992–2007. Fundam Clin Pharmacol. 2009;23:345–9. https://doi.org/10.1111/j.1472-8206.2009.00678.x . - PubMed
  14. Baumevieille M, Perri-Plande J, Miremont-Salame G, Daveluy A, Haramburu F. From psychoactive medicines to addictovigilance in French Public Health Code (1990–2017). Therapie. 2019;74:375–82. https://doi.org/10.1016/j.therap.2018.07.007 . - PubMed
  15. Daveluy A, Sauvaget L, Bastien A, Lapeyre-Mestre M, Collin C, Richard N, et al. Tamper-resistant prescription forms for narcotics in France: Should we generalize them? Fundam Clin Pharmacol. 2018;32:571–7. https://doi.org/10.1111/fcp.12368 . - PubMed
  16. Peyrière H, Nogue E, Eiden C, Frauger E, Charra M, Picot MC. Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area. Fundam Clin Pharmacol. 2016;30:466–75. https://doi.org/10.1111/fcp.12210 . - PubMed
  17. Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012;126:13–20. https://doi.org/10.1016/j.drugalcdep.2012.03.009 . - PubMed
  18. Micallef J, Jouanjus E, Mallaret M, Lapeyre MM. Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health. Therapie. 2019;74:579–90. https://doi.org/10.1016/j.therap.2019.09.005 . - PubMed
  19. Dupouy J, Palmaro A, Fatseas M, Auriacombe M, Micallef J, Oustric S, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-Year Cohort Study. Ann Fam Med. 2017;15:355–8. https://doi.org/10.1370/afm.2098 . - PubMed
  20. Ponte C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, et al. Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88–94. https://doi.org/10.1016/j.drugalcdep.2018.01.036 . - PubMed
  21. Ministrère des solidarités et de la santé. Base de données publique des médicaments. 2020. http://base-donnees-publique.medicaments.gouv.fr/ . Accessed 30 July 2021. - PubMed
  22. Delorme J, Chenaf C, Bertin C, Riquelme M, Eschalier A, Ardid D, et al. Chronic pain opioid-maintained patients receive less analgesic opioid prescriptions. Front Psychiatry. 2018;9:335. https://doi.org/10.3389/fpsyt.2018.00335 . - PubMed
  23. Haute Autorité de Santé (HAS). Avis de la transparence: Durogesic, February 2008. https://www.has-sante.fr . Accessed 30 July 2021. - PubMed
  24. Haute Autorité de Santé (HAS). Avis de la transparence: Oxycontin®, Oxynorm®, Oxynormoro®, September 2012. https://www.has-sante.fr . Accessed 30 July 2021. - PubMed
  25. Trouvin AP, Chenaf C, Riquelme M, Curis E, Nicolis I, Javier RM, et al. Opioid epidemic: does rheumatological practice favors risk for patients? National survey on rheumatologists’ opioid prescriptions and compliance to guidelines for strong opioid prescription. Jt Bone Spine. 2021;88: 105046. https://doi.org/10.1016/j.jbspin.2020.06.019 . - PubMed
  26. Muller AE, Clausen T, Sjogren P, Odsbu I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017. Scand J Pain. 2019;19:345–53. https://doi.org/10.1515/sjpain-2018-0307 . - PubMed
  27. Gisev N, Pearson SA, Blanch B, Larance B, Dobbins T, Larney S, et al. Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. Br J Clin Pharmacol. 2016;82:1123–33. https://doi.org/10.1111/bcp.13026 . - PubMed
  28. Ayoo K, Mikhaeil J, Huang A, Wasowicz M. The opioid crisis in North America: facts and future lessons for Europe. Anaesthesiol Intensive Ther. 2020. https://doi.org/10.5114/ait.2020.94756 . - PubMed
  29. Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7:13–21. https://doi.org/10.1007/s40122-018-0097-6 . - PubMed
  30. Bigal LM, Bibeau K, Dumbar S. Patterns in opioid prescription in the United States by region and prescribers over a 4-year period. J Opioid Manag. 2019;15:499–506. https://doi.org/10.5055/jom.2019.0541 . - PubMed
  31. Ojanpera I, Kriikku P, Vuori E. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. Int J Legal Med. 2016;130:1209–16. https://doi.org/10.1007/s00414-016-1358-8 . - PubMed
  32. Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157:1232–8. https://doi.org/10.1097/j.pain.0000000000000511 . - PubMed
  33. Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician. 2013;16:89–100. - PubMed
  34. Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, et al. Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017;72:491–501. https://doi.org/10.1016/j.therap.2017.01.010 . - PubMed
  35. Micallef J, Pauly V, Ponte C, Giocanti A, Pochard L, Frauger E, et al. French pharmacosurveillance of opioid analgesics: results of disproportionality analysis from OPPIDUM (Observation of psychoactive substance consumption). Fundam Clin Pharmacol. 2018;32:188–97. - PubMed
  36. Aknouche F, Guibert E, Tessier A, Alvarez JC, Lemaire-Hurtel AS, Kintz P. Unusual deaths in France: about 3 cases involving oxycodone. Toxicol Anal Clin. 2015;27:52–6. - PubMed
  37. Jouanjus E, Guernec G, Lapeyre-Mestre M, French AN. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018;32:306–22. https://doi.org/10.1111/fcp.12356 . - PubMed
  38. Tournebize J, Gibaja V, Frauger E, Authier N, Seyer D, Perri-Plande J, et al. French trends in the misuse of Fentanyl: From 2010 to 2015. Therapie. 2020;75:491–502. https://doi.org/10.1016/j.therap.2019.11.002 . - PubMed
  39. French Addictovigilance Network. Misuses and risks of transmucosal fentanyl. 2020: http://www.addictovigilance.fr/IMG/pdf/bulletin_addictovigilance_ftm_vf_site.pdf . Accessed 30 July 2021. - PubMed
  40. Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network? Fundam Clin Pharmacol. 2018;32:643–51. https://doi.org/10.1111/fcp.12401 . - PubMed
  41. Société française d'évaluation et de traitement de la douleur (SFETD). Utilisation des opioïdes forts dans la douleur chronique non cancéreuse chez l’adulte. 2016. https://www.sfetd-douleur.org/sites/default/files/u3349/recommandations/recos_opioides_forts_sfetd_version_longue.compressed.pdf . Accessed 30 July 2021. - PubMed
  42. Henry SG, Bell RA, Fenton JJ, Kravitz RL. Communication about chronic pain and opioids in primary care: impact on patient and physician visit experience. Pain. 2018;159:371–9. https://doi.org/10.1097/j.pain.0000000000001098 . - PubMed
  43. Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260–9. https://doi.org/10.1111/bcp.13892 . - PubMed
  44. Hägg S, Jonsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020;43:1235–54. https://doi.org/10.1007/s40264-020-00985-6 . - PubMed

Publication Types